I'm a doctor but not onco. Please explain me. It's my mom's report.
Reading File
Running Command
Reading File
Searching PubMed
breast fibromatosis desmoid tumor management
Finding Sources
Reading Article
Reading File
Finding Sources
Reading File
Finding Sources
I now have everything I need. Here is a thorough breakdown of the report for you.
Pathology Report - Mrs. Anuradha Panjabrao Pande, 49F
Right Breast Lump Biopsy - Tata Memorial Centre, June 24, 2026
What the Report Says in Plain Terms
The biopsy was sent to TMC for a second opinion (outside block for review). The pathologists at TMC have confirmed the diagnosis as:
Breast Fibromatosis (also called Desmoid Tumor / Mammary Fibromatosis / Desmoid-type Fibromatosis)
This is NOT a cancer. It does not metastasize. That is the single most important takeaway.
Understanding the Microscopy Findings
| Finding | What it Means |
|---|---|
| Spindle cell lesion | The tumor is made up of elongated (spindle-shaped) cells - this is the hallmark of fibromatosis |
| Bland elongated nuclei, indistinct nucleoli | The cells look "quiet" - no features of malignancy |
| Mild atypia | Slight nuclear irregularity, but well within the benign range |
| No necrosis | No cell death within the tumor - reassuring against malignancy |
| No atypical mitotic activity | No abnormal cell division - another marker against cancer |
| Collagenous background | Dense fibrous stroma typical of fibromatosis |
IHC Panel - Why Each Stain Was Done
The IHC panel is the key to confirming fibromatosis and ruling out other spindle cell tumors:
| Marker | Result | Interpretation |
|---|---|---|
| SMA (Smooth Muscle Actin) | Positive | Confirms myofibroblastic differentiation - classic for fibromatosis |
| Beta-catenin (nuclear) | Focally positive | This is pathognomonic. Fibromatosis has CTNNB1 gene mutations causing nuclear accumulation of beta-catenin. Nuclear (not just cytoplasmic) staining confirms the diagnosis |
| AE1/AE3 (pan-cytokeratin) | Negative | Rules out carcinoma (including spindle cell/metaplastic carcinoma) |
| SOX10 | Negative | Rules out nerve sheath tumors (schwannoma, MPNST) and myoepithelioma |
| CD34 | Negative | Rules out solitary fibrous tumor and other CD34+ spindle cell tumors. CD34 negativity is expected in fibromatosis |
| p53 | Wild type | No p53 mutation - further argues against malignancy |
| Mib1 (Ki-67) | 2-3% | Very low proliferation index - confirms the indolent, benign nature |
The IHC pattern (SMA+, nuclear beta-catenin+, CD34-, AE1/AE3-, SOX10-) is the textbook signature of fibromatosis. This is a well-characterized, internally consistent panel.
What is Breast Fibromatosis?
- A locally aggressive benign tumor that arises from the breast stroma/myofibroblasts
- It never metastasizes - it is not cancer
- Very rare - accounts for only ~0.2% of all breast tumors
- Typically presents as a firm, mobile palpable mass, average size ~2 cm
- On imaging it can look suspicious (spiculated on mammogram, hypoechoic on ultrasound) - which is why it often ends up being biopsied and sent for review
- Most fibromatosis is sporadic; a minority are associated with familial adenomatous polyposis (FAP/Gardner syndrome) - worth checking if there is any family history of colorectal polyps
Risk Context
Breast fibromatosis falls under the category of proliferative breast disease without atypia, which carries approximately a ~2x relative risk of future breast cancer development - the same ballpark as sclerosing adenosis. This is NOT a high-risk lesion; the risk figure simply means she should continue routine surveillance.
(Fischer's Mastery of Surgery 8th ed., p. 1380)
Management - What Happens Next
This is where there has been a genuine shift in practice in recent years:
Current options (multidisciplinary decision):
-
Active Surveillance (now preferred first line) - Multiple studies show the majority of breast fibromatosis lesions remain stable or actually regress spontaneously. Progression occurs in only ~10% of patients. This avoids surgery entirely in most cases.
-
Surgical excision - Previously the default. Still an option, especially if the lesion is growing or symptomatic. Importantly, positive margins do not clearly increase recurrence risk, so there is no mandate for wide excision.
-
Systemic therapy - If surgery is not feasible or the lesion progresses: tamoxifen, NSAIDs, tyrosine kinase inhibitors (sorafenib/imatinib) have been used. A gamma-secretase inhibitor, nirogacestat, was recently approved for desmoid tumors and is showing promise (PMID: 40888418).
-
Radiation - Controversial, reserved for progressive symptomatic unresectable disease only.
Key message from the 2024 review (PMID: 38751692, Kangas-Dick et al., World J Oncol): Traditional surgery-first approaches are being replaced by watchful waiting or medical management. There is currently no clear superiority of upfront resection over surveillance. Guidelines intentionally remain flexible given limited evidence.
Bottom Line for Your Mom
| Point | Detail |
|---|---|
| Diagnosis | Breast fibromatosis (benign, locally aggressive, non-metastasizing) |
| Is it cancer? | No |
| Will it spread? | No metastases ever reported |
| Can it recur locally? | Yes, local recurrence is possible if removed |
| Next step | Multidisciplinary breast team discussion (surgical oncology + medical oncology) |
| Follow-up | Clinical breast exam every 6 months + annual mammogram (+/- MRI) |
| FAP screening | Consider colonoscopy/genetic referral if family history of colorectal polyps |
The report has been issued by TMC (Tata Memorial Centre) which is one of India's premier cancer centers - the confirmation of diagnosis here is reliable. The good news is that this is a benign condition with very manageable options.
Sources: Fischer's Mastery of Surgery 8th ed., p. 1380 | Kangas-Dick et al., World J Oncol 2024 [PMID: 38751692] | Wu et al., Breast J 2024 [PMID: 39742373]
This is a shared conversation. Sign in to Orris to start your own chat.